MET and autosomal dominant polycystic kidney disease: Both of the kinase targets predicted in the mebendazole-ADPKD diffusion profile, VEGFR2 (KDR) and Abl, were inhibited by mebendazole at this concentration, while overall four targets with known links to ADPKD pathophysiology were represented: VEGFR1 (Flt1) and VEGFR2 (KDR) (Bello-Reuss et al., 2001; Tao et al., 2007), cyclin dependent kinase 1 (CDK1) (Zhang et al., 2021) and Met (Qin et al., 2010).